The ingredient narratives reshaping clean beauty.
Thiamidol
aka isobutylamido thiazolyl resorcinol
A 2026 vehicle-controlled human trial makes the endpoint gap more informative than generic brightening language: investigator scoring improved while patient assessment and digital colour analysis did not significantly differ.
- evidence of improvement on a studied hyperpigmentation score versus vehicle
- targeted pigmentation skincare
The trial used 0.2% Thiamidol. This is a study condition, not a universal formulation instruction.
Endpoint-specific benefit, a 12-week horizon, commercial funding and limited applicability to other pigmented lesions. Do not translate this into removal of all dark spots.
Moderate evidence — useful, but narrower than broad brightening claims imply.
The ingredient narratives reshaping clean beauty.
Thiamidol
aka isobutylamido thiazolyl resorcinol
A 2026 vehicle-controlled human trial makes the endpoint gap more informative than generic brightening language: investigator scoring improved while patient assessment and digital colour analysis did not significantly differ.
- evidence of improvement on a studied hyperpigmentation score versus vehicle
- targeted pigmentation skincare
The trial used 0.2% Thiamidol. This is a study condition, not a universal formulation instruction.
Endpoint-specific benefit, a 12-week horizon, commercial funding and limited applicability to other pigmented lesions. Do not translate this into removal of all dark spots.
Moderate evidence — useful, but narrower than broad brightening claims imply.